Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction

JAMA

Volumn 297, Issue 1, 2007, Pages 91-92

  Eikelboom, John W ^a,b   O'Donnell, Martin ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PEXELIZUMAB; PLACEBO;

ANGIOPLASTY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; EDITORIAL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW;

EID: 33846027093     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.1.91     Document Type: Editorial

References (15)

1. Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002;105:2332-2336.
2. Yasuda M, Takeuchi K, Hiruma M, et al. The complement system in ischemic heart disease. Circulation. 1990;81:156-163.
3. Eltzschig HK, Collard CD. Vascular ischaemia and reperfusion injury. Br Med Bull. 2004;70:71-86.
4. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement Inhibition in Myocardial Infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108:1184-1190.
5. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108:1176-1183.
6. Shernan SK, Fitch JC, Nussmeier NA, et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2004;77:942-949.
7. Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA. 2004;291:2319-2327.
8. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007;297:43-51.
9. Smith PK, Levy JH, Shernan SK. Pexelizumab, a terminal complement inhibitor in coronary artery bypass graft surgery: results from the Pexelizumab for the Reduction in Myocardial Infarction and Mortality in CABG II trial. In: Program and abstracts of the 55th Annual American College of Cardiology Scientific Session; March 11-14, 2006; Atlanta, Ga. Abstract 411-412.
10. Armstrong PW, Granger CB. Reflections on early stopping of a clinical trial. Am Heart J. 2006;152:407-409.
11. Hordijk-Trion M, Lenzen M, Wijns W, et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J. 2006;27:671-678.
12. Mahaffey KW, Van de Werf F, Shernan SK, et al. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. Am Heart J. 2006;152:291-296.
13. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005; 2:e124.
14. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1217-1221.
15. Lievre M, Menard J, Bruckert E, et al. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ. 2001;322:603-605.